版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
耳鼻咽喉頭頸外科學(xué)耳鼻咽喉頭頸外科學(xué)第二篇鼻科學(xué)及顱面疾病(3)第十一章
鼻黏膜高反應(yīng)性鼻病第一節(jié)
變態(tài)反應(yīng)性鼻炎R(shí)espiratorymucosainnoseThenasalmucosashowedbytransmi-ssionalelectromi-Croscope.ThepictureofnormalmucosashowedbynasalendoscopeNasalhyper-reactivityNasalcavity:FirstlineofairwaySensitivity:richnervedistributionMucosalcompound:respiratoryepithelialcellsGobletcellglands(serousormucous)richvesselsImmunecompound:Toll-likereceptorslymphocytes(T,B)serouscellsmastcellsepithelialcells
ResponseofnoseinducedbysomefactorsChallengefactors:enviromentalWeather、temperature、humidityinhalants:Dust、allergen、chemicalspollutionmostofaboveIntrinsic:nervous、stressordisappoint、depressoranxious
Nasalresponse——Protective
hyper-reactivityofNasalmucosaThedifferenceofnasalmucosalreactionbetweenphysiologicandpathologiccondition
高反應(yīng)性鼻病Definition:
HyperreactiveRhinopathyissymptomicdisorderandthereactionofnasalmucosainducedbystimuliexceednormallimitMainincluding:AllergicRhinitisNon-allergicrhinitis——coldairinducingrhinitisendocrinerhinitisdruginducingrhinitisnonallergicallergicrhinitiswitheosinophiliavasomotorrhinitis(idiopathicrhinitis)
AllergicrhinitisAllergicrhinitisisasymptomaticdisorderofthenoseinducedafterallergenexposurebyanimmunoglobulinE(IgE)-mediatedinflammationofthemembranesliningthenoseDifinitionofAllergicrhinitisKeypointofthedifinitionSusceptibleindividualInducedbyallergenexposureIgEmediatedmainlyNasalmucosainfalmmationMainsymptomsincludesneeze,rhinorrheaandobstructionallergenPollen:tree,grass,cropplantfugidustmitepetdanderMechanismofallergicinflammation-Th2responseTh2BIL-4變應(yīng)原NaiveThIgEIL-4IL-5釋放炎癥介質(zhì)毒性蛋白細(xì)胞因子釋放炎癥介質(zhì)和細(xì)胞因子Eo變應(yīng)性鼻炎免疫學(xué)機(jī)制-以Th2反應(yīng)為主的免疫性疾病嗜酸性粒細(xì)胞肥大細(xì)胞和嗜堿性粒細(xì)胞速發(fā)反應(yīng)(EarlyPhaseReaction)遲發(fā)反應(yīng)(LatePhaseReaction)抗原提呈細(xì)胞SymptomsNasalobstructionSymptoms>1hrdaylyLasting>4dsweeklysneezeNoserunningPale-edemamucosaNoseitchHowarethesymptomscaused?Irritationoffreenerveendings---- ItchingandsneezingIncreasedmucusproduction------ RhinorrhoeaVasodilation--------MucosacongestionIncreasedvascularpermeability----MucosaoedemaRelationshipbetweenupandlowairwayMorbidityofasthmainPatientswithallergicrhinitisis3timesmorethanonewhonoallergicrhinitis20%ofchildrenwithallergicrhinitiswilloccurasthmainlifelateRelationshipbetweenupandlowairwayMucosalinflammationispresentintheentireairwayofpatientswithallergicrhinitisand/orasthma.UpperairwayinflammationisassociatedwithbronchialhyperresponsivenessLowerairwayremodelingispresentinasthmatic,butalsoinallergicrhinitispatients.RelationshipbetweenupandlowairwayAllergicrhinitisandasthmaarecharacterizedbyaninflammatoryprocessthatismarkedhistologicallybytissueeosinophils,mastcells,Tlymphocytes,macrophages,andepithelialcells.inflammationImportantConceptOneairway,OnediseaseGrowsman-1997Worldwideprevalence
PrevalenceofAllergicrhinitisinCHINA(2007)IncreasingprevalenceofARThecausemaybeassociatedwithfactorsasfollows:Airpollution:exhaustparticle;ozone,NO2(nitrogendioxide),SO2(sulfurdioxide)Lifestyle:unsaturatedacidHyper-HygieneTheimpactofARonqualityofLiveQualityoflive(QOL):Sleepingworkstudyentertainmentsocialcommunicationsystemicfelling
AllergicrhinitisandItsimpactonasthma(ARIA2008)—theWHOGuideline:Allergicrhinitisisaglobalhealthproblemthatcausesmajorillnessanddisabilityworldwide.Itaffectssociallife,sleep,schoolandwork.
Bothallergicrhinitisandasthmaaresystemicinflammatoryconditionsandareoftenco-morbidities.Theeconomicimpactofallergicrhinitisissubstantial.
Intermittent
<4daysperweekor<4weeksClassficationofARPersistent≥4daysperweekand≥4weeksMildnormalsleepnoimpairmentofdailyactivities,sport,leisurenormalworkandschoolnotroublesomesymptomsModerate-severeoneormoreitemsabnormalsleepimpairmentofdailyactivities,sport,leisureabnormalworkandschooltroublesomesymptomsARIA2008,CHINAGuideofAR2009DiagnosisofARDiagnosisofARHistory—cornerstoneofdiagnosisDuringandseverityInducer:grasspollendampmatteroldclothingsandbeddingpadpet(cat,dog)Nasalhyper-reactivity:sneezingrhinorrheaResponsetoH1antihistaminetherapyApositivewheal>3mmdiameterreactionindicatesthatthepatientisproducingIgEantibodiestoaspecificallergen,andtakeninconjunctionwithapositivehistory,isevidencethattheallergenisresponsibleforthepatient’ssymptoms.ExplanationofSPTresultPositiveNotable:mayseenearly25%innormalEmphasizing:correspondingwithhistoryinformation:Yes——makediagnosisNo——maypredictive
Negativeexcludedrugeffectunknowallergenmaypresentnonallergic
SerumSpecificIgE(sIgE)DifferentialdiagnosisByexclusiveprocess(SPT;serumsIgE)Non-allergicnasalhyperreaciverhinitisVasomotorrhinitis(idiopathic)Non-allergiceosinophiliarhinitis(aspirinintolerance?)Hyper-reflectiverhinitis(Psubstance?)Endocrinerhinitis(estrogn)ManagementofARAllergenAvoidancePharmacotherapyImmunotherapyPharmacotherapyMedicationsusedtotreatallergicrhinits:AntihistaminesDecongestantsCorticosteroidsMastCellstabilizersAnticholinergicsAntileukotrienes(抗白三烯藥)Anti-HistaminesActbypreventinghistaminefrombindingtotheH1-receptorsPrimarilyhelpfulincontrollingSneezing,itching&rhinorrhoea;ineffectiveinreleivingnasalblockage1stgenerationanti-histamines -chlorpheniramine -diphenylhydramine2ndgenerationanti-histamines -cetrizine -azelastine -fexofenadine -loratadineAnti-HistaminesIndications:mildintermittentorpersistentrhinitismoderate-severe——combinedwithintranasalcorticosteroidsGenerally,Secondgenerationantihistaminesisfirstchoiceadvantage:longtermeffectnosedativeRoutesofadministrationoralorintranasalIntranasalcorticosteroidtherapyPotenttopicalactivityAdministrationoflowdosesdirectlyatsiteofactionConsiderableefficacyatlowdosesHightopical:systemicactivityratiosRapidfirst-passhepaticmetabolismofanysystemicallyabsorbeddrug,tocompoundswithnegligibleactivityIntranasalcorticosteroidsIndications:Moderate-severeintermittentorpersistentorcomplicatedwithasthmaAdvantage:anti-inflammationeffectissignificantlysuperiortoantihistainessafe,nosystemicsideeffectAnti-leukotrieneAnti-leukotrieneshouldbegivenforpatientswithbronchialsymptomsorseverenasalsymptomsActionsofVariousNasalPreparationsintheTreatmentofRhinitisNasalPreparationSneezingItchingRhinorrhoeaCongestionAntihistamines++++++++++++0Anticholinergics00+++++0Corticosteroids++++++++++++++++NasalPreparationSneezingItchingRhinorrhoeaCongestionDecongestants00++++++Mastcellstabiliser+++++++++0Antileukotrienes+++++0++++SpecificImmunotherapy(SIT)SITisthepracticeofadministeringgraduallyincreasingquantitiesofanallergenextracttoanallergicsubjecttoamelioratesymptomsassociatedwiththesubsequentexposuretothecausativeallergen.Specificimmunotherapyn
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 咖啡烘焙技術(shù)與操作手冊(cè)(標(biāo)準(zhǔn)版)
- 零售業(yè)顧客服務(wù)與銷售技巧指南(標(biāo)準(zhǔn)版)
- 2025至2030中國(guó)金屬包裝材料循環(huán)利用經(jīng)濟(jì)性研究報(bào)告
- 2025至2030連鎖零售市場(chǎng)擴(kuò)張策略與區(qū)域布局優(yōu)化研究報(bào)告
- 幼兒園五一勞動(dòng)節(jié)活動(dòng)方案及教案設(shè)計(jì)
- 醫(yī)院醫(yī)療事故上報(bào)流程及處理方案
- 職業(yè)病防治工作方案編制指南
- 2025-2030燃料電池汽車技術(shù)研發(fā)應(yīng)用推廣市場(chǎng)前景政策環(huán)境行業(yè)競(jìng)爭(zhēng)態(tài)勢(shì)分析報(bào)告
- 2025-2030熱氣球研發(fā)制造大氣壓力極大空間科學(xué)領(lǐng)域勤考察
- 2025-2030湘菜行業(yè)知識(shí)產(chǎn)權(quán)保護(hù)現(xiàn)狀與建議
- XX小學(xué)傳統(tǒng)體育游戲集錦
- GB/T 3906-20203.6 kV~40.5 kV交流金屬封閉開關(guān)設(shè)備和控制設(shè)備
- 2023年電大當(dāng)代中國(guó)政治制度機(jī)考拼音排版絕對(duì)好用按字母排序
- GB 39669-2020牙刷及口腔器具安全通用技術(shù)要求
- 精益生產(chǎn)試題與答案
- 醫(yī)院關(guān)于主治醫(yī)師晉升前到急診科、重癥醫(yī)學(xué)科輪轉(zhuǎn)鍛煉工作的管理規(guī)定
- L1會(huì)計(jì)研究方法論簡(jiǎn)介課件
- 防治水培訓(xùn)課件
- 按摩穴位保健養(yǎng)生課件
- 食材配送投標(biāo)服務(wù)方案
- 大學(xué)生心理健康教育全套課件
評(píng)論
0/150
提交評(píng)論